YJH-012

Primary objective: To evaluate the safety and tolerability of a single dose of YJH-012 in healthy adult male participants and patients with hyperuricemia. Secondary objectives: 1. To evaluate the pharmacokinetic (PK) characteristics of a single dose of YJH-012 in healthy adult male participants and patients with hyperuricemia. 2. To evaluate the pharmacodynamic (PD) characteristics of a single dose of YJH-012 in healthy adult male participants and patients with hyperuricemia. 3. To evaluate the immunogenicity (ADA) of a single dose of YJH-012 in healthy adult male participants and patients with hyperuricemia. Exploratory objectives: 1. To explore the main metabolites of YJH-012 in plasma and urine after a single dose in healthy adult male participants and patients with hyperuricemia. 2. To explore the excretion characteristics of YJH-012 in urine after a single dose in healthy adult male participants and patients with hyperuricemia. 3. To explore the effect of YJH-012 on the QT interval after a single dose in healthy adult male participants and patients with hyperuricemia.